Omega Advisors’s Kite Pharma, Inc. KITE Stock Holding History

Omega Advisors’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-53,761	Closed	-$4.22M	–	101
2017 Q1	$4.22M	Buy	+53,761	New	+$3.32M	0.17%	65

Other funds holding KITE

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Omega Advisors's KITE Position: Q2 2017 in Review

Omega Advisors sold out of Kite Pharma, Inc. (KITE) in Q2 2017, closing a stake of 53,761 shares — an estimated $4.22M sold.

Omega Advisors first reported a position in KITE in Q1 2017 and held it in 1 quarter. The position peaked at $4.22M in Q1 2017. 220 funds tracked by Wall St. Rank hold KITE as of Q2 2017.

Omega Advisors reported no remaining Kite Pharma, Inc. position as of Q2 2017 after selling out during the quarter.
Omega Advisors sold 53,761 Kite Pharma, Inc. shares in Q2 2017, an estimated $4.22M.
Omega Advisors first reported a position in Kite Pharma, Inc. in Q1 2017 and held it in 1 quarter.
Omega Advisors's Kite Pharma, Inc. position peaked at $4.22M in Q1 2017.
220 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q2 2017.

Based on Omega Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.